Overview

Peri-operative SLOG for Localized Pancreatic Cancer

Status:
Recruiting
Trial end date:
2023-08-24
Target enrollment:
Participant gender:
Summary
1. To evaluate the efficacy of neoadjuvant chemotherapy SLOG in localized pancreatic cancer 2. To evaluate the safety profile in patients with pancreatic cancer who receive neoadjuvant SLOG 3. To collect tumor tissue and peripheral blood samples from the patients for a comprehensive biomarker evaluation
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Treatments:
Gemcitabine
Leucovorin
Oxaliplatin